References
- Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459–75.
- Oncley JL, Melin M, Richert DA, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and β1-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949;71:541–50.
- U.S. Food and Drug Administration. Source Plasma. Code of Federal Regulations 21, Section 640, Subpart G (2018). Available from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm.
- Brorson K, Campbell J, Carter J, et al. Virus Filtration Technical Report No. 41. PDA J Pharm Sci Technol 2008;62:S-4.
- Dichtelmüller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009;49:1931–43.
- Morgenthaler JJ. Securing viral safety for plasma derivatives. Transfus Med Rev 2001;15:224–33.
- Thorpe SL, Sands D, Fox B, et al. A global standard for anti-D immunoglobulin: international collaborative study to evaluate a candidate preparation. Vox Sang 2003;85:313–21.
- Berry D, DiGuardo M, Mo YD, Wehrli G. Anti-D from alloimmunization versus RhIG: detective work in the blood bank and transfusion medicine services. Transfusion 2018;58:2490–4.
- Hannon JL, Clarke G. Laboratory management of perinatal patients with apparently “new” anti-D. Immunohematology 2016;32:108–11.
- Sandler SG, Gottschall JL. Postpartum Rh immunoprophylaxis. Obstet Gynecol 2012;120:1428–38.
- American College of Obstetrics and Gynecology. ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology. Int J Gynecol Obstet 1999;66:63–70.
- Hartwell EA. Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists. Am J Clin Pathol 1998;110:281–92.
- Sandler SG, Sathiyamoorthy S. Laboratory methods for detecting fetomaternal hemorrhage. Immunohematology 2010;26:92–103.
- Sandler SG, Delaney M, Gottschall JL, for the CAP Transfusion Medicine Resource Committee. Proficiency tests reveal the need to improve laboratory assays for fetomaternal hemorrhage for Rh immunoprophylaxis. Transfusion 2013;53:2098–102.
- Fung MK, Eder AE, Spitalnik SL, Westhoff CM, Eds. Technical manual. 19th ed. Bethesda, MD: AABB, 2017:604.
- Moise KJ, Gandhi M, Boring NH, et al. Circulating cell-free DNA to determine the fetal RHD status in all three trimesters of pregnancy. Obstet Gynecol 2016;128:1340–6.
- Zhu YJ, Zheng YR, Li L, et al. Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free DNA: a meta analysis. J Matern Fetal Neonatal Med 2014;27:1839–44.
- Kent J, Farrell AM, Soothill P. Routine administration of anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnancy Childbirth 2014;14:87.
- de Haas M, Thurik FF, van der Ploeg CPV, et al. Sensitivity of fetal RHD screening for safe guidance or targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ 2016;355:i1589.
- Kennedy MS, McNanie, Waheed A. Detection of ante-D following antepartum injections of Rh immune globulin. Immunohematology 1998;14:138–40.
- Lee D, Contreras M, Robson SC, et al. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynecologists. Transfus Med 1999;9:93–7.
- Pollack W, Ascari WQ, Crispen JF, et al. Studies on Rh prophylaxis II. Rh immune prophylaxis after transfusion with Rh-positive blood. Transfusion 1971;11:340–4.
- Bowman HS, Mohn JF, Lambert R. Prevention of maternal immunization after accidental transfusion of D(Rho)-positive blood. Vox Sang 1972;22:385–96.
- Goldfinger D, McGinniss MH. Rh-incompatible platelet transfusions: risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971;284:942–4.
- McGinniss MH, Bronson WR, Freireich E, Kliman A. Formation of red cell antibodies in response to platelet transfusions (abstract). Transfusion 1963;3:426.
- Cid J, Yazer MH, Lozano M, et al. Platelet transfusion and respecting patient D type. Curr Opion Hematol 2015;22:540–6.
- Anderson B, Shad AT, Gootenberg JE, Sandler SG. Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD). Am J Hematol 1999;60:245–7.
- Ewing CA, Rumsey DH, Langeberg AF, Sandler SG. Immunoprophylaxis using intravenous Rh immune globulin should be standard practice when selected D-negative platelets are transfused with D-positive random donor platelets. Immunohematology 1998;14:133–7.
- Savasman CM, Sandler SG. Serologic aspects of treating immune thrombocytopenic purpura using intravenous immune globulin. Immunohematology 2001;17:106–10.
- Sandler SG. Intravenous immune globulin for treating immune thrombocytopenic purpura. Current Opin Hematol 2001;8:417–20.
- Sandler SG. Treating immune thrombocytopenic purpura and preventing Rh alloimmunization using Intravenous Rho (D) immune globulin. Transfus Med Rev 2001;15:67–76.
- Sandler SG, Tutuncuoglu SO. Immune thrombocytopenic purpura: current management practices. Expert Opin Pharmacother 2004;5:2515–27.
- Sandler SG. Review: immune thrombocytopenic purpura: an update for immunohematologists. Immunohematology 2004;20:112–7.
- Mikesell KV, George MR, Castellani WJ, et al. Evaluation of different testing methods for identification of RhIG in red blood cell antibody detection. Transfusion 2015;55:1444–50.
- Weisbach V, Kohnhauser T, Zimmermann R, et al. Comparison of the performance of microtube column systems and solid-phase systems and the tube low-ionic-strength solution additive indirect antiglobulin test in the detection of red cell alloantibodies. Transfus Med 2006;16:276–84.
- Delaflor-Weiss E, Chizhevsky V. Implementation of gel testing for antibody screening and identification in a community based hospital, a 3 year experience. Lab Med 2005;8:489–92.
- National Blood Authority. Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics. 2003. Available from www.blood.gov.au/system/files/documents/glines-anti-d.pdf.
- Australian and New Zealand Society of Blood Transfusion Ltd. Guidelines for blood grouping & antibody screening in the antenatal and perinatal setting. 3rd ed. 2007. Available from www.seqirus.com.au/docs/471/745/ANGuidelines_2007[1].pdf.
- White J, Qureshi H, Massey E, et al. Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med 2016;26:246–63.
- Qureshi H, Massey E, Kirwan D, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 2014;24:8–20.
- Szkotak AJ, Lunty B, Nahirniak S, Clarke G. Interpretation of pretransfusion testing in obstetrical patients who have received antepartum Rh immunoglobulin prophylaxis. Vox Sang 2016;110:51–9.
- Irving C, Crennan M, Vanniasinkam T. Can serological methods help distinguish between prophylactic and alloimmune anti-D? Transfus Med 2017;27:362–8.
- Rushin J, Rumsey DH, Ewing CA, Sandler SG. Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin. Transfusion 2000;40:551–4.